Human CCL22 / MDC Protein, Fc Tag

Numéro de produit/spécification
Prix
Availability
Qté
CC2-H5257-20ug
$185.00
In Stock - Delivery in 1-2 business days
CC2-H5257-50ug
$370.00
In Stock - Delivery in 1-2 business days
CC2-H5257-1mg
$3,400.00
In Stock - Delivery in 1-2 business days
CC2-H5257
Montant du produit :
$ 0
0
Ajouter au panier
Suggestion de nouveau produit Request Quote
Contact Us
Contact Us
Montant du produit:
$ 0
0
Ajouter au panier
  • Détails du produit
  • Affichage des données
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

MDC, ABCD-1, SCYA22, STCP-1, DC, B-CK, A-152E5.1

Source

Human CCL22, Fc Tag (CC2-H5257) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Gln 93 (Accession # O00626-1).

Predicted N-terminus: Gly 25

Molecular Characterization

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 34.5 kDa. The protein migrates as 35-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Introduction de fond

MDC is the high-affinity ligand for CCR4. Secreted by tumor-associated macrophages and dendritic cells, CCL22 recruits immunosuppressive CCR4+ Tregs into the tumor microenvironment. This chemokine axis dampens anti-tumor immunity, and its blockade aims to exclude Tregs and unleash effector T-cell responses.